Fig. 1 · Structure
Documents & Downloads
Carbidopa hydrochloride
Decarboxylase Inhibitor
Carbidopa hydrochloride is a decarboxylase inhibitor that primarily targets the conversion of levodopa to dopamine in the peripheral system. This action increases the bioavailability of levodopa to the central nervous system, enhancing its therapeutic efficacy in the treatment of Parkinson's disease. Additionally, carbidopa hydrochloride acts as an aryl hydrocarbon receptor (AhR) ligand, exhibiting anticancer properties by inhibiting the proliferation of pancreatic cancer cells and tumors. Its dual functionality highlights the potential for further clinical applications in neurology and oncology research.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 65132-60-7 |
| Applications | Decarboxylase Inhibitor |
| Formula | C10H15ClN2O4 |
| Molecular Weight | 262.69 |
| Synonyms | (S)-(-)-Carbidopa hydrochloride |
| SMILES | OC(C=C1C[C@@](NN)(C)C(O)=O)=C(C=C1)O.Cl |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.